Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design
Jan 23, 2014
Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002 in...
Oct 7, 2013
Generics Bulletin profiles the exciting potential of Prosonix' respiratory pipeline and...
Aug 16, 2013
Final Patient Completes Prosonix’ Phase 2 Clinical Study with PSX1002 in Moderate to Severe...
18 March 2014
Orlando, FL, USA
4-8 May 2014
Fajardo, Puerto Rico